Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17

NCT05838755 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05838755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05838755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
September 20, 2023
Completion date
February 17, 2025
Enrollment
147 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

pain